Washington Oregon Biotech Networks

Partner Content from Thermo Fisher: Scaling your cell culture workflow for success, read this insightful article: https://conta.cc/41n8Uht As the demand for protein therapeutics grows, scaling your cell culture workflow is crucial. This article outlines key factors such as medium selection, feed systems, and supplier choices to mitigate risks and avoid costly delays. Learn how to enhance your manufacturing process and ensure timely delivery of therapies. #CellCulture #Biologics #ProteinTherapeutics #Manufacturing #Healthcare

HawkSoft Named an Oregon Top Workplace for 10th Consecutive Year https://lnkd.in/grGyPq_i HawkSoft credits its decade-long high employee satisfaction rates to the company’s core values, commitment to private ownership, and enduring family-like culture. CANBY, Ore., Dec. 23, 2024 /PRNewswire/ — Oregon-based HawkSoft, developer of the HawkSoft Insurance Platform for independent… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

OHSU is hit with a lawsuit over lost wages, age discrimination https://lnkd.in/g-8BXSbu Dr. Sanjiv Kaul is the latest high-ranking professor to take issue with the university in recent weeks. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Dr. Albert Starr, who developed the first artificial heart valve, dies at 98 https://lnkd.in/gfJxdFzQ Dr. Albert Starr was a world-renowned cardiothoracic surgeon who performed the first triple valve surgery. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Hi Seattle Biotech Talent Acquisition Professionals! I’m looking to connect with local biotech TA professionals who are passionate about helping people find their perfect candidate and growing our amazing biotech community. We’d love to get you involved in upcoming networking events where you can: 🔍 Highlight your open roles 💬 Help job seekers navigate their search 🤝 Create some awesome WIN-WIN opportunities—finding the right candidates for your team while helping folks land their dream jobs If this sounds interesting, DM me or connect with me here—I’d love to chat and share more details! 😊 Let’s come together to make these events even better and strengthen our biotech community. 🌟 📣 Oh, and please repost and share this post with your network so we can reach all the local biotech company’s TA professionals out there! Looking forward to connecting with you all and making Seattle biotech amazing! 🚀

Omeros antibody improves overall survival by 68% in rare condition, new analysis finds https://lnkd.in/gFPFb4XQ Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a new data analysis that found the investigational treatment improved overall survival by 68% for patients with a rare, life-threatening complication of a bone marrow transplant. Given the results, Omeros hopes the anti-MASP-2 antibody narsoplimab will become the first treatment on the market in the indication, according to a Dec. 19 release . The biotech’s stock has jumped 70% since market close yesterday, rising from $7.46 per share last night to $12.71 as of 11 a.m. ET today. Omeros is testing narsoplimab as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in both adults and children who have had hematopoietic stem cell transplantation (HSCT). The Seattle-based biotech evaluated its candidate among 28 patients with TA-TMA in a phase 2 trial, dubbed OMS721-TMA-001 , that wrapped in 2020. Omeros… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Seattle research nonprofit shares in up to $52 million award for AI-powered disease prevention https://lnkd.in/gm_qdRZD The research organization is tackling multiple projects with the federally funded award. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Washington Research Foundation awards 12 three-year postdoctoral fellowships https://lnkd.in/g6mt2D96 Early-career researchers will complete projects in natural sciences and engineering at Fred Hutch Cancer Center, the University of Washington and Washington State University to address areas of urgent public need SEATTLE, Dec. 18, 2024 /PRNewswire-PRWeb/ — Washington Research Foundation… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA https://lnkd.in/gaGDwhVJ SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). Th Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Parse Biosciences Welcomes Admera Health as Newest Member of Certified Service Provider Network https://lnkd.in/gGdH2dbn SEATTLE–(BUSINESS WIRE)–Parse Biosciences Welcomes Admera Health as Newest Member of Certified Service Provider Network Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks